ABBV-383 (ABBV-383), a BCMA * CD3 bispecific T-cell engager (BiTE), targets and inhibits the B-cell maturation antigen (BCMA) while concurrently activating the T-cell surface glycoprotein CD3 complex. This compound is utilized in research focused on multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases.
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
